Stefan Bittner
University of Mainz
ImmunologyExperimental autoimmune encephalomyelitisMultiple sclerosisMedicineBiology
What is this?
Publications 152
#1Erik Ellwardt (University of Mainz)H-Index: 6
#2Leoni RolfesH-Index: 3
Last. Clemens Warnke (University of Mainz)
view all 11 authors...
Objective To provide first real-world experience on patients with MS treated with the B cell–depleting antibody ocrelizumab. Methods We retrospectively collected data of patients who had received at least 1 treatment cycle (2 infusions) of ocrelizumab at 3 large neurology centers. Patients9 characteristics including premedication, clinical disease course, and documented side effects were analyzed. Results We could identify 210 patients (125 women, mean age ± SD, 42.1 ± 11.4 years) who had receiv...
1 CitationsSource
#1Beatrice Wasser (University of Mainz)H-Index: 3
#2Dirk Luchtman (University of Mainz)H-Index: 5
Last. Stefan Bittner (University of Mainz)H-Index: 29
view all 9 authors...
To study the role of myeloid cells in the central nervous system (CNS) in the pathogenesis of multiple sclerosis (MS) and its animal model, experimental autoimmune encephalomyelitis (EAE), we used intravital microscopy, assessing local cellular interactions in vivo in EAE animals and ex vivo in organotypic hippocampal slice cultures. We discovered that myeloid cells actively engulf invading living Th17 lymphocytes, a process mediated by expression of activation-dependent lectin and its T cell-bi...
#1Stefan Bittner (University of Mainz)H-Index: 29
#2Falk Steffen (University of Mainz)H-Index: 2
Last. Sven G. MeuthH-Index: 36
view all 31 authors...
Abstract Background We aim to evaluate serum neurofilament light chain (sNfL), indicating neuroaxonal damage, as a biomarker at diagnosis in a large cohort of early multiple sclerosis (MS) patients. Methods In a multicentre prospective longitudinal observational cohort, patients with newly diagnosed relapsing-remitting MS (RRMS) or clinically isolated syndrome (CIS) were recruited between August 2010 and November 2015 in 22 centers. Clinical parameters, MRI, and sNfL levels (measured by single m...
1 CitationsSource
#1Sinah EngelH-Index: 2
#2Falk SteffenH-Index: 2
Last. Felix LuessiH-Index: 19
view all 7 authors...
Objective To investigate the association of serum neurofilament light chain (sNfL) levels with CSF parameters in clinically isolated syndrome (CIS) and early relapsing-remitting MS (RRMS), taking into account radiologic and clinical parameters of disease activity. Methods Simultaneously collected serum and CSF samples of 112 untreated patients newly diagnosed with CIS or RRMS were included in this cross-sectional study. CSF parameters were obtained as part of routine diagnostic tests. sNfL level...
#1Sargis Abrahamyan (Charité)
#2Bettina Eberspächer (Charité)H-Index: 2
Last. Thomas Grüter (RUB: Ruhr University Bochum)H-Index: 3
view all 29 authors...
Objective To determine the prevalence of antibodies to Epstein-Barr virus (EBV) in a large cohort of patients with early multiple sclerosis (MS). Methods Serum samples were collected from 901 patients with a clinically isolated syndrome (CIS) or early relapsing–remitting multiple sclerosis (RRMS) participating in the German National MS cohort, a prospective cohort of patients with early MS with stringent inclusion criteria. Epstein-Barr nuclear antigen (EBNA)-1 and viral capsid antigen (VCA) ant...
#1Sinah Engel (University of Mainz)H-Index: 2
#2Christiane Graetz (University of Bern)
Last. Luisa KlotzH-Index: 23
view all 30 authors...
Objective To assess the impact of APOE polymorphisms on cognitive performance in patients newly diagnosed with clinically isolated syndrome (CIS) or relapsing-remitting MS (RRMS). Methods This multicenter cohort study included 552 untreated patients recently diagnosed with CIS or RRMS according to the 2005 revised McDonald criteria. The single nucleotide polymorphisms rs429358 (e4) and rs7412 (e2) of the APOE haplotype were assessed by allelic discrimination assays. Cognitive performance was eva...
#1Erik Ellwardt (University of Mainz)H-Index: 6
#2Christina F. Vogelaar (University of Mainz)H-Index: 11
Last. Dirk Luchtman (University of Mainz)H-Index: 5
view all 6 authors...
Abstract The humanized anti-CD52 antibody alemtuzumab is successfully used in the treatment of multiple sclerosis (MS) and is thought to exert most of its therapeutic action by depletion and repopulation of mainly B and T lymphocytes. Although neuroprotective effects of alemtuzumab have been suggested, direct effects of anti-CD52 treatment on glial cells and neurons within the CNS itself have not been investigated so far. Here, we show CD52 expression in murine neurons, astrocytes and microglia,...
2 CitationsSource
#1Julia Loos (University of Mainz)H-Index: 1
#2Steffen Pfeuffer (WWU: University of Münster)H-Index: 5
Last. Stefan Bittner (University of Mainz)H-Index: 29
view all 9 authors...
Based on clinical, immunological and histopathological evidence, MOG-IgG-associated encephalomyelitis (MOG-EM) has emerged as a distinct disease entity different from multiple sclerosis (MS) and aquaporin-4-antibody-positive neuromyelitis optica spectrum disorder (NMOSD). MOG-EM is associated with a broader clinical phenotype including optic neuritis, myelitis, brainstem lesions and acute disseminated encephalomyelitis with a substantial clinical and radiological overlap to other demyelinating C...
Although the impact of Th17 cells on autoimmunity is undisputable, their pathogenic effector mechanism is still enigmatic. We discovered soluble N-ethylmaleimide-sensitive factor attachment receptor (SNARE) complex proteins in Th17 cells that enable a vesicular glutamate release pathway that induces local intracytoplasmic calcium release and subsequent damage in neurons. This pathway is glutamine dependent and triggered by binding of beta1-integrin to vascular cell adhesion molecule 1 (VCAM-1) o...
2 CitationsSource